… EGFR mutation testing and erlotinib treatment among a population-… and/or receipt of erlotinib
were associated with survival. In … Cancer Institute (NCI) Patterns of Care (POC) lung cancer …

… in treatment, non–smallcell lung cancer (NSCLC) remains the leading global cause of cancer-…
, with a median survival of 10 to 12 months with aggressive therapy.Therefore, improving …

… cells treated with erlotinib or cisplatin, breast cancer cells treated with a HER2 TKI, and
melanoma cells treated … a beneficial adjunct to therapy in a broad range of clinical applications. …

… during EGFR-TKI treatment (250 mg daily gefitinib or 150 mg daily erlotinib) between April
… Two of the 15 patients received gefitinib and erlotinib treatment; therefore, we analyzed 17 …

… Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone …
cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor …

… We identified two phase 2 trials that assessed the activity of erlotinib plus bevacizumab
as first-line treatment for EGFR-positive NSCLC: BELIEF and JO25567. The BELIEF study …

… in the treatment of patients with non-small cell lung cancer. A … This drug profile focuses on
the development of erlotinib, an … Results of clinical trials are reviewed, two trials of erlotinib in …

… kinase inhibitor erlotinib in athymic nude mice bearing non-small cell lung cancer (NSCLC) …
At the end of this study (day 47 post-tumor implantation, treatment day 19), erlotinib 100 mg/…

… Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small
cell lung cancer (… for treatment of locally advanced, inoperable, or metastatic pancreatic …

… ) erlotinib is an established option for second-line treatment of patients with advanced NSCLC
[1., 2., 3.]. Treatment with erlotinib … that survival outcomes with erlotinib are similar to those …